IP Library Granted Patent US 9,957,299
Granted Patent B2
US 9,957,299 · App. 15/135,098 · Granted May 1, 2018

Peptidomimetic macrocycles

Inventors: Vincent Guerlavais (Arlington, MA); Noriyuki Kawahata (West Roxbury, MA)
Assignee: AILERON THERAPEUTICS, INC.
C07K7/64C07K7/56C07K14/4746A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,957,299
App. No.
15/135,098
Granted
May 1, 2018
Kind
B2
Abstract

The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.

Claims (54)

1. A peptidomimetic macrocycle comprising an amino acid sequence which is at least 60% identical to the amino acid sequence of: SEQ ID NO. 163.

2. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an amino acid sequence which is at least 80% identical to the amino acid sequence of: SEQ ID NO. 163.

3. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an amino acid sequence which is at least 90% identical to the amino acid sequence of: SEQ ID NO. 163.

4. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an amino acid sequence which is at least 95% identical to the amino acid sequence of: SEQ ID NO. 163.

5. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an amino acid sequence which is: SEQ ID NO. 163.

6. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises a helix.

7. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an α-helix.

8. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an α,α-disubstituted amino acid.

9. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises a crosslinker linking the α-positions of at least two amino acids within the peptidomimetic macrocycle.

10. The peptidomimetic macrocycle of claim 9 , wherein at least one of the two amino acids is an α,α-disubstituted amino acid.

11. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle has the formula:

wherein:

each A, C, D, and E is independently a natural or non-natural amino acid, and each D and E independently optionally includes a capping group;

each B is independently a natural or non-natural amino acid, amino acid analog, or

each R 1 and R 2 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;

each R 3 is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 ;

each L is independently a macrocycle-forming linker of the formula -L 1 -L 2 -;

each L 1 and L 2 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R 4 —K—R 4 —], each optionally substituted with R 5 ;

each R 4 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ;

each R 5 is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent;

each R 6 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R 7 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, each optionally substituted with R 5 , or forms part of a cyclic structure with a D residue;

each R 8 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, each optionally substituted with R 5 , or forms part of a cyclic structure with an E residue;

each v and w is independently an integer from 1-1000;

u is an integer from 1-10;

each x, y and z is independently an integer from 0-10; and

each n is independently an integer from 1-5.

12. The peptidomimetic macrocycle of claim 11 , wherein L does not include a thioether or a triazole.

13. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises a cross linker linking a backbone amino group of a first amino acid within the peptidomimetic macrocycle to a second amino acid within the peptidomimetic macrocycle.

14. The peptidomimetic macrocycle of claim 13 , wherein the peptidomimetic macrocycle has the formula (IV) or (IVa):

wherein:

each A, C, D, and E is independently a natural or non-natural amino acid, and each D and E independently optionally includes a capping group;

each B is independently a natural or non-natural amino acid, amino acid analog, or

each R 1 and R 2 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each non-H group being unsubstituted or substituted with halo-, or part of a cyclic structure with an E residue;

each R 3 is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, each non-H group being optionally substituted with R 5 ;

each L 1 and L 2 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R 4 —K—R 4 —], each optionally substituted with R 5 ;

each R 4 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ;

each R 5 is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent;

each R 6 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R 7 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 ;

each v and w is independently an integer from 1-1000;

u is an integer from 1-10;

each x, y and z is independently an integer from 0-10; and

each n is independently an integer from 1-5.

15. The peptidomimetic macrocycle of claim 14 , wherein L 1 and L 2 either alone or in combination do not include a thioether or a triazole.

16. The peptidomimetic macrocycle of claim 11 , wherein L 1 and L 2 are independently alkylene, alkenylene or alkynylene.

17. The peptidomimetic macrocycle of claim 11 , wherein L 1 and L 2 are independently C 3 -C 10 alkylene or C 3 -C 10 alkenylene.

18. The peptidomimetic macrocycle of claim 17 , wherein L 1 and L 2 are independently C 3 -C 6 alkylene or C 3 -C 6 alkenylene.

19. The peptidomimetic macrocycle of claim 11 , wherein R 1 and R 2 are H.

20. The peptidomimetic macrocycle of claim 11 , wherein R 1 and R 2 are independently alkyl.

21. The peptidomimetic macrocycle of claim 11 , wherein R 1 and R 2 are methyl.

22. A pharmaceutical composition comprising the peptidomimetic macrocycle of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2016
From: GUERLAVAIS, VINCENT; KAWAHATA, NORIYUKI
To: AILERON THERAPEUTICS, INC.
Reel/Frame 040473/0299 →
Continuity (6)
Continuation 14460848 · Aug 15, 2014
Division 13816880
Provisional Application 61373638 · Aug 13, 2010
Provisional Application 61373701 · Aug 13, 2010
Provisional Application 61374163 · Aug 16, 2010
Related Publication 20160257716A1 · Sep 8, 2016